The Wheel Strategy on ABT (Abbott Laboratories): Full Setup, Sizing, and Real-World Numbers

By Nomi Ali Tariq · August 4, 2026 · 8 min read ·Wheel Strategy

What's in this guide

1. Why ABT as a wheel candidate 2. The risks — segment diversity + regulatory 3. Strike selection on ABT 4. Position sizing 5. A worked example — full cycle 6. Special considerations 7. The mistakes wheelers make on ABT 8. Next steps

ABT (Abbott Laboratories) is one of the most diversified healthcare companies — medical devices (FreeStyle Libre glucose monitoring, cardiac products), diagnostics (COVID tests, immunoassays), nutrition (Ensure, Similac), and established pharmaceuticals. For wheelers, ABT offers Dividend King status (50+ years of consecutive increases), low IV meaning smooth cycles, and healthcare defensive characteristics.

1. Why ABT as a wheel candidate

Dividend King — 50+ years of consecutive dividend increases
Solid dividend (~2% yield)
Low IV (~15-22%) — smooth cycles, small drawdowns
Deep options liquidity — tight spreads
Diversified segments — medical devices + diagnostics + nutrition + pharma
FreeStyle Libre franchise — dominant continuous glucose monitoring
Non-cyclical healthcare demand — recession-resistant

2. The risks — segment diversity + regulatory

Segment-specific risks: different regulatory + competitive dynamics per segment
COVID test revenue normalization: post-pandemic diagnostic revenue has declined
Nutrition segment issues: Similac formula recall history creates ongoing legal exposure
Drug pricing regulation: pharma segment exposed to IRA pressure
FDA regulatory: medical device approvals + recalls

3. Strike selection on ABT

Situation	Suggested delta	DTE
Normal conditions	0.20-0.25 delta	35-45 DTE
Elevated IV (regulatory/recall news)	0.15-0.20 delta	35-45 DTE
Low IV (common)	0.20-0.25 delta	30-45 DTE

4. Position sizing

ABT at $130 requires $13,000 per contract. Sizing rules:

Max 20% of wheel capital in ABT specifically
Never let ABT + JNJ + MRK + LLY + PFE + UNH + ABBV exceed combined 30% (healthcare concentration)
Keep 25%+ cash cushion

5. A worked example — full cycle

ABT at $130, IV rank 40. You have $13,000 for this position:

Day	Action	Result	Cumulative P/L
0	Sell 1 ABT $125P, 35 DTE, 0.22 delta	Collect $180 premium	+$180
26	Put worth $85 (53% profit). Buy to close.	Free capital.	+$95 net
26	Sell 1 ABT $126P, 35 DTE, 0.22 delta	Collect $190 premium	+$285
61	ABT at $132 at expiration; put expired worthless.	Kept full $190.	+$285

$285 on $13,000 in 2 months = ~2.2% for cycle, ~13% annualized on premium. Add dividend when assigned (~$0.60/qtr = ~2% additional annual yield).

6. Special considerations

Dividend

ABT pays ~$2.40/year per share (~1.8% yield at $130). Dividend King status (50+ years of increases). Approximately $60/quarter per contract when holding shares.

FreeStyle Libre franchise

ABT's continuous glucose monitoring (CGM) business is a major growth driver. Watch Libre revenue trajectory in quarterly commentary.

Similac litigation ongoing

ABT faces ongoing lawsuits related to premature infant formula (Similac). Multi-billion litigation exposure. Watch for major verdict/settlement news that can move ABT 3-8%.

7. The mistakes wheelers make on ABT

Mistake #1: Overallocating to healthcare

ABT + JNJ + MRK + LLY + PFE + UNH + ABBV correlate on sector news. Cap combined healthcare at 30%.

Mistake #2: Ignoring Similac litigation risk

Multi-billion litigation exposure. Big verdict or settlement can move ABT 5-10%. Wheelers should track major litigation developments.

8. Next steps

Verify ABT fits your account — $13,000 per contract
Use 0.20-0.25 delta, 35-45 DTE puts
Watch FreeStyle Libre growth + Similac litigation

For real weekly wheel trades I run in my own account, the Omega Membership shares the trade plan. Or grab the free Starter Kit.

Ready to shadow real wheel trades?

The Omega Membership is the weekly trade plan I run in my own account — Sunday market prep, live calls, and the members' Discord.

See the membership → Free Starter Kit

About the author

Nomi Ali Tariq spent 18 years in financial services — fund accounting at JPMorgan, reporting at Credit Suisse, risk systems at Goldman Sachs, and platform work at a $25B private-equity firm. Options-trained via Maverick Trading in 2021. He runs the wheel in his own account every week. The Omega Wheel — no hype, just the math and the real risks. Read the full story.

Frequently asked questions

Is ABT a good stock for the wheel strategy?

Yes. Pros: Dividend King (50+ years of consecutive increases), solid ~2% dividend, low IV (~15-22%) means smooth cycles, deep options liquidity, diversified segments (medical devices + diagnostics + nutrition + pharma), FreeStyle Libre CGM franchise, non-cyclical healthcare demand. Cons: segment-specific risks, COVID test revenue normalization, Similac formula recall litigation exposure, drug pricing regulation on pharma segment, FDA regulatory risks.

How much capital do I need to wheel ABT?

One contract requires ~$13,000 at $130/share × 100. Practical minimum for responsible sizing is around $65k+ total capital.

ABT vs JNJ for the wheel — which is better?

Both diversified healthcare Dividend Kings/Aristocrats with similar profiles. ABT = more segment diversity (medical devices + diagnostics + nutrition + pharma), slightly higher IV, ongoing Similac litigation. JNJ = post-Kenvue-spinoff more focused on pharma + medical devices, larger Talc litigation resolved. Both work; JNJ slightly higher quality; ABT slightly more diverse.

Does ABT pay a dividend?

Yes — ~$2.40/year per share (~1.8% yield at $130), paid quarterly. Dividend King with 50+ years of consecutive increases. Approximately $60/quarter per contract when holding shares.

What is FreeStyle Libre and why does it matter for ABT?

FreeStyle Libre is Abbott's continuous glucose monitoring (CGM) system for diabetics — one of the two dominant CGM franchises globally (Dexcom is the other). ~$7B+ revenue business growing double-digits. Major growth driver for ABT. Watch quarterly Libre revenue commentary as key growth metric.

What is the Similac litigation risk?

ABT faces ongoing lawsuits related to Similac premature infant formula allegedly causing NEC (necrotizing enterocolitis). Multi-billion aggregate litigation exposure. Individual jury verdicts have ranged from small to $60M+ awards. Not yet resolved. Wheelers should watch for major verdict/settlement news that can move ABT 3-8%.

What are the biggest risks of wheeling ABT?

Five specific ones: (1) segment-specific risks — different regulatory/competitive dynamics per segment, (2) COVID test revenue normalization from post-pandemic decline, (3) Similac formula recall litigation ongoing multi-billion exposure, (4) drug pricing regulation on pharma segment (IRA), (5) FDA regulatory risks on medical devices.

When should I skip wheeling ABT?

Four situations: (1) 7 days before earnings, (2) during major Similac litigation news windows, (3) during FDA regulatory action periods on ABT products, (4) if you already have significant healthcare exposure through JNJ/MRK/LLY/PFE/UNH/ABBV.